PTHS Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. (PTHS) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $2.25 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.1% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Pelthos Therapeutics Inc.
Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens.
Sector
Healthcare
Industry
Biotechnology